RT Journal Article
SR Electronic
T1 Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.21.20199109
DO 10.1101/2020.09.21.20199109
A1 Bandopadhyay, Purbita
A1 D’Rozario, Ranit
A1 Lahiri, Abhishake
A1 Sarif, Jafar
A1 Ray, Yogiraj
A1 Paul, Shekhar Ranjan
A1 Roy, Rammohan
A1 Maiti, Rajshekhar
A1 Chaudhuri, Kausik
A1 Bagchi, Saugata
A1 Maiti, Ayan
A1 Perwez, Md. Masoom
A1 Sarkar, Biswanath Sharma
A1 Roy, Devlina
A1 Chakraborty, Rahul
A1 Vasudevan, Janani Srinivasa
A1 Sharma, Sachin
A1 Biswas, Durba
A1 Maiti, Chikam
A1 Saha, Bibhuti
A1 Bhattacharya, Prasun
A1 Pandey, Rajesh
A1 Chatterjee, Shilpak
A1 Paul, Sandip
A1 Ganguly, Dipyaman
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.21.20199109.abstract
AB In a randomized control trial on convalescent plasma therapy (CPT) in severe COVID-19, we characterized the nature, in terms of abundance of forty eight cytokines, and dimensions, in terms of their interrelationships, of the hyper-immune activation-associated ‘cytokine storm’ in patients suffering from acute respiratory distress syndrome. We found reduced plasma level of the chemokine MCP3 to be a key correlate for clinical improvement, irrespective of therapeutic regimen. We also identified an anti-inflammatory role of CPT independent of its neutralizing antibody content, and a linear regression analysis revealed that neutralizing antibodies as well as the anti-inflammatory effect of CPT both contribute to marked immediate reductions in hypoxia, as compared to patients on standard therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinical Trial Registry of India No. CTRI/2020/05/025209Funding StatementFunding for this study was from Council of Scientitific Industrial Research (CSIR), Govt. of India (MLP-129)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study had ethical approval from the Institutional Review Boards of CSIR-Indian Institute of Chemical Biology, Kolkata, India (IICB/IRB/2020/3P), Institutional Review Boards of Medical College Hospital, Kolkata (MC/KOL/IEC/NON-SPON/710/04/2020), India and Infectious Disease & Beleghata General Hospital (ID & BG Hospital), Kolkata, India (IDBGH/Ethics/2429). The RCT was approved by Central Drugs Standard Control Organisation (CDSCO) under Directorate General of Health Services, Ministry of Health & Family Welfare, Govt. of India (approval no. CT/BP/09/2020) and registered with Clinical Trial Registry of India (CTRI), under Indian Council of Medical Research, India.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available with the corresponding author and will be shared on request.